Gilead Sciences, Inc. (GILD) and Gritstone Oncology, Inc. (GRTS) have entered into a collaboration, option and license agreement. The companies will develop an HIV-specific therapeutic vaccine using Gritstone's prime-boost vaccine platform, with antigens developed by Gilead.
Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment. Gilead will be responsible for conducting a phase 1 study for the HIV-specific therapeutic vaccine. Gritstone is also eligible to receive up to an additional $725 million, as well as mid single-digit to low double-digit tiered royalties on net sales.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.